Share this article
Share this article
NEW YORK, May 7, 2021 /PRNewswire/ Longview Acquisition Corp. II (NYSE: LGV.U) (the Company ) announced that, commencing May 10, 2021, holders of the units sold in the Company s initial public offering of 69,000,000 units, may elect to separately trade the shares of Class A common stock and redeemable warrants included in the units. Those units not separated will continue to trade on the New York Stock Exchange (the NYSE ) under the symbol LGV.U, and the shares of Class A common stock and redeemable warrants that are separated will trade on the NYSE under the symbols LGV and LGV WS, respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company s transfer agent, in order to separate the units into shares of Class A common stock and redeemable warrants.
SPAC Attack: CT tech firms going public, raising billions through popular alternative IPO method
hartfordbusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hartfordbusiness.com Daily Mail and Mail on Sunday newspapers.
10 Best Stocks To Buy According To Billionaire Larry Robbins
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
By Reuters Staff
1 Min Read
(Reuters) - Bausch Health Companies Inc on Thursday named insider Sam Eldessouky as its new finance chief, at a time when the Canadian drugmaker looks to speed up the spinoff of eye care unit Bausch + Lomb.
Current CFO Paul Herendeen will take on the role of advisor to the chairman and chief executive officer, the company said.
Eldessouky’s appointment comes amid calls from activist investor Glenview Capital Management for Bausch to spin-off Bausch + Lomb by year-end. The company in August said it would offload the unit into a separate publicly listed firm.
Bausch last month agreed to add directors from Icahn Group to its board, weeks after activist investor Carl Icahn disclosed a nearly 8% stake.